Note: 1.25 mg of levalbuterol base is equivalent to 2.5 mg of albuterol (Lötvall 2001; NAEPP 2007). Nebulized therapy may be preferred for patients who cannot effectively use an inhaler (Lemanske 2021).
Asthma, acute exacerbation:
Mild to moderate exacerbations (initial home management): Note: Patients with worsening symptoms despite initial care should seek immediate medical attention (GINA 2022).
Metered-dose inhaler (45 mcg/actuation): Oral inhalation: 2 to 4 inhalations with spacer every 20 minutes for 3 doses, then every 1 to 4 hours based on response and tolerability (Fanta 2021; Kirenga 2015; NAEPP 2007; Roy 2003).
Nebulization solution: Oral inhalation: 1.25 mg every 20 minutes for 3 doses, then every 1 to 4 hours based on response and tolerability (Fanta 2021; GINA 2022; NAEPP 2007; NAEPP 2020).
Moderate to severe exacerbations (management in primary or acute care settings): Note: For severe exacerbations, use in combination with an inhaled short-acting muscarinic antagonist and other adjunctive therapies. For patients who have more severe symptoms or who cannot effectively use an inhaler, nebulized therapy may be preferred (Fanta 2021).
Metered-dose inhaler (45 mcg/actuation): Oral inhalation: Initial: 4 inhalations with spacer every 20 minutes for 3 doses, then taper based on response and tolerability (eg, to 2 to 4 inhalations every 1 to 4 hours as needed). If insufficient response, may increase to 6 or 8 inhalations/dose (Fanta 2021).
Nebulization solution: Oral inhalation: 1.25 to 2.5 mg every 20 minutes for 3 doses, then every 1 to 4 hours as needed based on response and tolerability (Fanta 2021; GINA 2022; NAEPP 2007; NAEPP 2020).
Asthma, intermittent symptom relief (alternative agent): Note: Use on an as-needed basis (reliever therapy) rather than regularly scheduled (GINA 2022).
Metered-dose inhaler (45 mcg/actuation): Oral inhalation: 2 inhalations with spacer every 4 to 6 hours as needed; in some patients, 1 inhalation every 4 hours as needed may be sufficient (maximum dose: 2 inhalations every 4 hours).
Nebulization solution: Oral inhalation: Initial: 0.63 mg to 1.25 mg every 6 to 8 hours as needed, up to 3 doses per 24 hours (maximum dose: 1.25 mg 3 times daily) (Lemanske 2021; manufacturer's labeling).
Chronic obstructive pulmonary disease:
Acute exacerbation: Note: Optimal dosing not well defined. Adjust dose according to clinical symptom resolution and tolerability (GOLD 2021; Stoller 2021). Although similar efficacy exists among formulations, some experts prefer nebulized therapy during severe chronic obstructive pulmonary disease exacerbations (Stoller 2021). May combine with an inhaled short-acting muscarinic antagonist (GOLD 2021; Stoller 2021).
Nebulization solution: Oral inhalation: 0.63 to 1.25 mg every 1 hour for 2 to 3 doses, then every 2 to 4 hours as needed (Stoller 2021).
Metered-dose inhaler (45 mcg/actuation): Oral inhalation: 1 to 2 inhalations every 1 hour for 2 to 3 doses, then every 2 to 4 hours as needed; for patients requiring emergency department or hospital-based care, may increase to 4 inhalations every hour for 2 to 3 doses. For patients requiring mechanical ventilation, up to 8 inhalations may be used if needed (Stoller 2021).
Intermittent symptom relief: Note: Use for intermittent symptoms on an as-needed basis rather than regularly scheduled. In patients who have moderate to severe symptoms or who are at high risk of exacerbation, one or more additional long-acting agents should be used for maintenance therapy. May be used in combination with an inhaled short-acting muscarinic antagonist (Ferguson 2021; GOLD 2021).
Metered-dose inhaler (45 mcg/actuation): Oral inhalation: 2 inhalations every 4 to 6 hours as needed; in some patients, 1 inhalation every 4 to 6 hours may be sufficient (maximum dose: 2 inhalations every 4 hours).
Nebulization solution: Oral inhalation: 0.63 mg 3 times daily at intervals of 6 to 8 hours as needed; dosage may be increased to 1.25 mg 3 times daily as needed with close monitoring for adverse effects (maximum dose: 1.25 mg 3 times daily) (Donohue 2006).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
There are no dosage adjustments provided in the manufacturer’s labeling. Use high doses with caution; drug clearance is decreased.
There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).
(For additional information see "Levalbuterol: Pediatric drug information")
Asthma: Note: Scheduled daily levalbuterol use is not recommended for long-term maintenance treatment (GINA 2021; NAEPP 2007). Increasing use or regular use >2 days/week for symptom control (except prevention of exercise-induced bronchospasm) indicates inadequate control and need for additional long-term control therapy (NAEPP 2007; NAEPP 2020).
Acute symptom relief: Note: For use as an as-needed reliever therapy for acute symptoms outside of an exacerbation; beta agonists should be used in combination with inhaled corticosteroids (ICS) for acute symptom relief in select patients ≥4 years of age; this may be accomplished by either administering as-needed albuterol immediately followed by ICS or using a combination ICS and formoterol inhaler (Bisgaard 2006; GINA 2021).
Metered-dose inhaler: 45 mcg/actuation:
Children ≥4 years and Adolescents: Oral inhalation: 2 inhalations every 4 to 6 hours as needed (NAEPP 2007); 1 inhalation every 4 hours may be sufficient in some patients; maximum dose: 2 inhalations every 4 hours (manufacturer's labeling).
Nebulization: Limited data available in ages <6 years:
Infants and Children ≤4 years: Oral inhalation: 0.31 to 1.25 mg every 4 to 6 hours as needed (NAEPP 2007).
Children 5 to <12 years: Oral inhalation: 0.31 to 0.63 mg every 8 hours as needed (NAEPP 2007).
Children ≥12 years and Adolescents: Oral inhalation: 0.63 to 1.25 mg every 6 to 8 hours as needed for up to 3 doses per 24 hours (NAEPP 2007; manufacturer's labeling).
Acute exacerbation: Note: Use for progressively worsening asthma symptoms not responding to as-needed reliever therapy. Beta agonists are often used in conjunction with systemic glucocorticoids in patients with acute exacerbations.
Home management: Note: Patients with severe symptoms or worsening symptoms despite initial care should seek immediate medical attention.
Metered-dose inhaler: 45 mcg/actuation:
Children ≥4 years and Adolescents: Oral inhalation: 2 to 4 inhalations every 20 minutes as needed for 2 to 3 doses; patients with more severe symptoms may require up to 6 inhalations/dose (NAEPP 2007); if initial response is good, lengthen dosing frequency and administer 2 to 6 inhalations every 3 to 4 hours for 24 to 48 hours (NAEPP 2007).
Nebulization: Limited data available in ages <6 years:
Infants and Children: Oral inhalation: Usual dose: 0.63 to 1.25 mg every 20 minutes for 3 doses if needed (Hardasmalani 2005; NAEPP 2007); if initial response is good, lengthen dosing frequency and administer 0.63 to 1.25 mg every 3 to 4 hours for 24 to 48 hours; reported range: 0.31 to 1.25 mg/dose (NAEPP 2007).
Adolescents: Oral inhalation: Usual dose: 1.25 mg every 20 minutes for 3 doses if needed (Hardasmalani 2005; NAEPP 2007); if initial response is good, lengthen dosing frequency and administer 1.25 mg every 3 to 4 hours for 24 to 48 hours; reported range: 0.63 to 2.5 mg/dose (AAP [Shenoi 2020]; NAEPP 2007).
Primary care/acute care management:
Metered-dose inhaler: 45 mcg/actuation: Infants, Children, and Adolescents (limited data available in ages <4 years): Oral inhalation: 4 to 8 inhalations every 20 minutes for 3 doses, then every 1 to 4 hours (AAP [Shenoi 2020]; NAEPP 2007).
Nebulization (AAP [Shenoi 2020]; NAEPP 2007): Note: Nebulization is preferred for patients who are unable to effectively use a metered-dose inhaler due to age, agitation, or severity of the exacerbation (NAEPP 2007). For severe exacerbations, addition of ipratropium may be considered if poor response to initial aggressive short-acting beta2-agonist (SABA) therapy in an acute care setting (ie, emergency department). Ipratropium has not been shown to provide further benefit (eg, after first 24 hours) once the patient is hospitalized (GINA 2021; NAEPP 2007).
Infants and Children: 0.075 mg/kg/dose (minimum dose: 1.25 mg/dose; maximum dose: 2.5 mg/dose) every 20 minutes for 3 doses, then 0.075 to 0.15 mg/kg/dose (maximum dose: 5 mg/dose) every 1 to 4 hours as needed.
Adolescents: 1.25 to 2.5 mg every 20 minutes for 3 doses, then 1.25 to 5 mg every 1 to 4 hours as needed.
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
There are no dosage adjustments provided in the manufacturer's labeling. Use high doses with caution; drug clearance is decreased.
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
Refer to adult dosing, starting with lowest dose; titrate cautiously.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Aerosol, Inhalation, as tartrate [strength expressed as base]:
Xopenex HFA: 45 mcg/actuation (15 g)
Generic: 45 mcg/actuation (15 g)
Nebulization Solution, Inhalation, as hydrochloride [strength expressed as base]:
Generic: 0.31 mg/3 mL (3 mL); 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 1.25 mg/0.5 mL (1 ea, 30 ea)
Nebulization Solution, Inhalation, as hydrochloride [strength expressed as base, preservative free]:
Xopenex: 0.31 mg/3 mL (3 mL); 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL)
Xopenex Concentrate: 1.25 mg/0.5 mL (1 ea, 30 ea)
Generic: 0.31 mg/3 mL (3 mL); 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 1.25 mg/0.5 mL (1 ea, 30 ea)
Yes
Xopenex HFA 15 g canisters contain 200 inhalations.
Inhalation: For oral inhalation only.
Metered-dose inhaler: Shake well before use, avoid spraying in the eyes. Prime with 4 test sprays prior to first use or if inhaler has not been used for more than 3 days. Clean actuator (mouthpiece) weekly with warm water and air dry thoroughly. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler. Each inhaler contains 200 actuations, discard when the display window shows zero.
Nebulization solution: Safety and efficacy were established when administered with the following nebulizers: PARI LC Jet, PARI LC Plus, as well as the following compressors: PARI Master, Dura-Neb 2000, and Dura-Neb 3000. Concentrated solution should be diluted prior to use. Compatibility with other medications (eg, budesonide, ipratropium) in nebulizer has been reported (Burchett 2010; Kamin 2014); also refer to institution-specific policies. Blow-by administration is not recommended, use a mask device if patient unable to hold mouthpiece in mouth for administration.
Oral inhalation: In children <4 years of age, a face mask with either the metered-dose inhaler or nebulizer is recommended (GINA 2021; NAEPP 2007).
Metered-dose inhaler: Shake well before use. Prime the inhaler (before first use or if it has not been used for more than 3 days) by releasing 4 test sprays into the air away from the face. Use with a valved spacer in patients ≤5 years of age and spacer with a mask for patients <3 years of age or until proper technique is demonstrated (GINA 2021). Clean actuator (mouthpiece) at least weekly with warm water and air dry thoroughly. The dose indicator tells you how many doses are left; do not immerse cannister in water or use "float test" to determine number of inhalations left. When the indicator turns red and reads "20", the patient should contact the pharmacy for a refill. Discard inhaler when the dose indicator window displays "0".
Nebulization: Dilution required for concentrated solution. Safety and efficacy were established when administered with the following nebulizers: PARI LC Jet, PARI LC Plus, as well as the following compressors: PARI Master, Dura-Neb 2000, and Dura-Neb 3000. Blow-by administration is not recommended, use a mask device if patient unable to hold mouthpiece in mouth for administration. Compatibility with other medications (eg, budesonide, ipratropium) in nebulizer has been reported (Burchett 2010; Kamin 2014); also refer to institution-specific policies.
Bronchospasm: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (eg, asthma).
Xopenex may be confused with Xanax
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%:
Central nervous system: Headache (children: 12%)
Gastrointestinal: Vomiting (children: 11%)
Infection: Viral infection (≤12%)
Respiratory: Rhinitis (6% to 11%)
>2% to 10%:
Cardiovascular: Tachycardia (adolescents and adults: 3%)
Central nervous system: Nervousness (adolescents and adults: 3% to 10%), dizziness (adolescents and adults: 3%), migraine (adolescents and adults: 3%), anxiety (adolescents and adults: ≤3%), pain (adolescents and adults: ≤3%)
Dermatologic: Skin rash (children: 8%), urticaria (children: 3%)
Gastrointestinal: Diarrhea (children: 2% to 6%; adolescents and adults: <2%), dyspepsia (adolescents and adults: ≤3%)
Hematologic & oncologic: Lymphadenopathy (≤3%)
Neuromuscular & skeletal: Tremor (adolescents and adults: ≤7%), leg cramps (adolescents and adults: ≤3%), weakness (children: 3%), myalgia (≤2%)
Respiratory: Pharyngitis (7% to 10%), asthma (9%), cough (adolescents and adults: 4%), sinusitis (adolescents and adults: 4%), flu-like symptoms (adolescents and adults: ≤4%), bronchitis (children: 3%), nasal mucosa swelling (1% to 3%)
Miscellaneous: Fever (children: 9%), accidental injury (children 5% to 9%; adolescents and adults: 3%)
Frequency not defined:
Endocrine & metabolic: Decreased serum potassium, increased heart rate, increased serum glucose, paradoxical bronchospasm
Hypersensitivity: Hypersensitivity reaction (including bronchospasm, oropharyngeal edema)
<2%, postmarketing, and/or case reports: Acne vulgaris, anaphylaxis, angina pectoris, angioedema, atrial fibrillation, cardiac arrhythmia, chest pain, chills, constipation, conjunctivitis, dry throat, dysmenorrhea, dyspnea, ECG abnormality, epistaxis, extrasystoles, eye pruritus, gastroenteritis, gastroesophageal reflux disease, hematuria, hyperesthesia (hand), hypertension, hypokalemia, hypotension, insomnia, metabolic acidosis, nausea, otalgia, paresthesia, pulmonary disease, supraventricular cardiac arrhythmia, syncope, vertigo, voice disorder, vulvovaginal candidiasis, xerostomia
Hypersensitivity to levalbuterol, albuterol, or any component of the formulation
Concerns related to adverse effects:
• Bronchospasm: Rarely, life-threatening paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response. Discontinue immediately and treat with an alternative therapy. Paradoxical bronchospasm is frequently associated with first use of a new canister or vial.
• Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, anaphylaxis, oropharyngeal edema) have been reported.
Disease-related concerns:
• Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, or hypertension); beta agonists may cause elevation in blood pressure and heart rate and result in CNS stimulation/excitation. Beta-2 agonists may also increase risk of arrhythmias and electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.
• Diabetes: Use with caution in patients with diabetes mellitus; beta2-agonists may increase serum glucose and aggravate ketoacidosis.
• Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.
• Hypokalemia: Use with caution in patients with hypokalemia; beta2-agonists may decrease serum potassium.
• Renal impairment: Use with caution in patients with renal impairment; drug clearance is decreased.
• Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.
Other warnings/precautions:
• Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.
• Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Atomoxetine: May enhance the tachycardic effect of Beta2-Agonists. Risk C: Monitor therapy
Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy
Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. Risk C: Monitor therapy
Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. Risk C: Monitor therapy
Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists. Risk X: Avoid combination
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider therapy modification
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Risk C: Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy
Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy
Kratom: May enhance the adverse/toxic effect of Sympathomimetics. Risk X: Avoid combination
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Risk D: Consider therapy modification
Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy
Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine. Risk X: Avoid combination
Methacholine: Beta2-Agonists (Short-Acting) may diminish the therapeutic effect of Methacholine. Management: Hold short-acting beta2 agonists for 6 hours before methacholine use. Risk D: Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists. Risk C: Monitor therapy
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy
QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Risk C: Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy
Theophylline Derivatives: Beta2-Agonists may enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, sympathomimetic effects may be increased. Theophylline Derivatives may enhance the hypokalemic effect of Beta2-Agonists. Risk C: Monitor therapy
Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy
Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists. Risk C: Monitor therapy
Maternal use of beta2 agonists is not associated with an increased risk of fetal malformations (GINA 2022).
Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth and gestational diabetes) (ERS/TSANZ [Middleton 2019]; GINA 2022).
Pregnant patients should be treated with a short-acting beta-2 agonist (SABA) for acute asthma exacerbations (GINA 2022). Maternal asthma symptoms should be monitored monthly (ERS/TSANZ [Middleton 2020], GINA 2022). If high doses of a SABA are required within 48 hours of delivery, monitoring of glucose concentrations in the newborn for 24 hours is recommended, especially in preterm infants (GINA 2022). Levalbuterol is not approved for the management of preterm labor.
Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (OTIS) (877-311-8972 or http://mothertobaby.org). Patients may also enroll themselves.
It is not known if levalbuterol is present in breast milk.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of exposure to the infant, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.
Asthma symptoms; FEV1, peak flow, and/or other pulmonary function tests; heart rate, blood pressure, CNS stimulation; arterial blood gases (if condition warrants); serum potassium, serum glucose (in selected patients)
Relaxes bronchial smooth muscle by action on beta2-receptors with little effect on heart rate
Onset of action (as measured by a 15% increase in FEV1):
Metered-dose inhaler: 5.5 to 10.2 minutes; Peak effect: 76 to 78 minutes
Nebulization solution: 10 to 17 minutes; Peak effect: 1.5 hours
Duration (as measured by a 15% increase in FEV1):
Metered-dose inhaler: 3 to 4 hours (up to 6 hours in some patients)
Nebulization solution: 5 to 6 hours (up to 8 hours in some patients)
Absorption: A portion of inhaled dose is absorbed to systemic circulation
Metabolism: Metabolized primarily in the gastrointestinal tract via SULT1A3 (sulfotransferase)
Half-life elimination: 3.3 to 4 hours
Time to peak, serum: Nebulization solution: Children: 0.3 to 0.6 hours, Adults: 0.2 hours
Excretion: Urine (80% to 100%), feces (<20%)
Altered kidney function: Racemic albuterol clearance decreased by 67% in patients with creatinine clearance of 7 to 53 mL/minute.
Aerosol (Levalbuterol Tartrate Inhalation)
45 mcg/ACT (per gram): $4.91
Aerosol (Xopenex HFA Inhalation)
45 mcg/ACT (per gram): $5.46
Nebulization (Levalbuterol HCl Inhalation)
0.31 mg/3 mL (per mL): $0.67 - $2.24
0.63 mg/3 mL (per mL): $0.67 - $2.24
1.25 mg/0.5 mL (per each): $6.70
1.25 mg/3 mL (per mL): $0.67 - $2.24
Nebulization (Xopenex Concentrate Inhalation)
1.25 mg/0.5 mL (per each): $8.54
Nebulization (Xopenex Inhalation)
0.31 mg/3 mL (per mL): $3.96
0.63 mg/3 mL (per mL): $3.96
1.25 mg/3 mL (per mL): $3.96
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
